tetano
Editor, Senior Moderator
Mycoses. 2020 Apr 27. doi: 10.1111/myc.13096. [Epub ahead of print]
COVID-19 Associated Pulmonary Aspergillosis.
Koehler P[SUP]1,[/SUP][SUP]2[/SUP], Cornely OA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], B?ttiger BW[SUP]5[/SUP], Dusse F[SUP]5[/SUP], Eichenauer DA[SUP]1[/SUP], Fuchs F[SUP]6[/SUP], Hallek M[SUP]1[/SUP], Jung N[SUP]1[/SUP], Klein F[SUP]7[/SUP], Persigehl T[SUP]8[/SUP], Rybniker J[SUP]1[/SUP], Kochanek M[SUP]1[/SUP], B?ll B[SUP]1[/SUP], Shimabukuro-Vornhagen A[SUP]1[/SUP].
Author information
Abstract
OBJECTIVES:
Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates Coronavirus disease 19 (COVID-19) associated invasive aspergillosis at a single center in Cologne, Germany.
METHODS:
A retrospective chart review of all patients with COVID-19 ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Germany.
RESULTS:
COVID-19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS.
CONCLUSION:
Clinicians caring for patients with ARDS due to COVID-19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co-infection.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Aspergillus; ECMO; ICU; SARS-CoV-2; isavuconazole; voriconazole
PMID:32339350DOI:10.1111/myc.13096
COVID-19 Associated Pulmonary Aspergillosis.
Koehler P[SUP]1,[/SUP][SUP]2[/SUP], Cornely OA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], B?ttiger BW[SUP]5[/SUP], Dusse F[SUP]5[/SUP], Eichenauer DA[SUP]1[/SUP], Fuchs F[SUP]6[/SUP], Hallek M[SUP]1[/SUP], Jung N[SUP]1[/SUP], Klein F[SUP]7[/SUP], Persigehl T[SUP]8[/SUP], Rybniker J[SUP]1[/SUP], Kochanek M[SUP]1[/SUP], B?ll B[SUP]1[/SUP], Shimabukuro-Vornhagen A[SUP]1[/SUP].
Author information
Abstract
OBJECTIVES:
Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates Coronavirus disease 19 (COVID-19) associated invasive aspergillosis at a single center in Cologne, Germany.
METHODS:
A retrospective chart review of all patients with COVID-19 ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Germany.
RESULTS:
COVID-19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS.
CONCLUSION:
Clinicians caring for patients with ARDS due to COVID-19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co-infection.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Aspergillus; ECMO; ICU; SARS-CoV-2; isavuconazole; voriconazole
PMID:32339350DOI:10.1111/myc.13096